Salvatore Guccione
Overview
Explore the profile of Salvatore Guccione including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pappalardo M, Sipala F, Nicolosi M, Guccione S, Ronsisvalle S
Molecules
. 2024 Nov;
29(22).
PMID: 39598735
In recent years, the advent of computational techniques to predict the potential activity of a drug interacting with a receptor or to predict the structure of unidentified proteins with aberrant...
2.
Ma O, Ronsisvalle S, Basile L, Xiang A, Tomasella C, Sipala F, et al.
Biomed Pharmacother
. 2022 Dec;
158:114141.
PMID: 36542987
Diabetic neuropathy (DN) is a long-term complication of diabetes mellitus, affecting different periphery nerve systems including sensory and motor neurons. Hyperglycemia is the major cause of DN with symptoms such...
3.
4.
Ramsay R, Basile L, Maniquet A, Hagenow S, Pappalardo M, Saija M, et al.
Molecules
. 2020 Dec;
25(24).
PMID: 33322203
The irreversible inhibitors of monoamine oxidases (MAO) slow neurotransmitter metabolism in depression and neurodegenerative diseases. After oxidation by MAO, hydrazines, cyclopropylamines and propargylamines form a covalent adduct with the flavin...
5.
Ronsisvalle S, Panarello F, Spadaro A, Franchini S, Pappalardo M, Guccione S, et al.
Future Med Chem
. 2020 Sep;
12(22):2001-2018.
PMID: 32972243
Central and peripheral analgesia without adverse effects relies on the identification of μ-opioid agonists that are able to activate 'basal' antinociceptive pathways. Recently developed μ-selective benzomorphan agonists that are not...
6.
Tomasella C, Floris M, Guccione S, Pappalardo M, Basile L
Mol Inform
. 2020 Sep;
40(3):e2000087.
PMID: 32954671
Endogenous peptides as part of physiological processes are targets of interest when it comes to finding desirable therapeutics which are able to modulate molecular interactions. The major limits presented by...
7.
Spadaro A, Basile L, Pappalardo M, Bonaccorso C, Rao M, Ronsisvalle S, et al.
J Chem Inf Model
. 2020 Aug;
60(10):5162-5171.
PMID: 32818373
Functional antitumor vaccine constructs are the basis for active tumor immunotherapy, which is useful in the treatment of many types of cancers. MUC1 is one key glycoprotein for targeting and...
8.
Ronsisvalle S, Spadaro A, Tomasello B, Basile L, Panarello F, Franchini S, et al.
Future Med Chem
. 2019 Apr;
11(11):1245-1258.
PMID: 30974972
Despite the serious side effects, analgesics acting on opioid receptors are still considered the best way to get antinociception. Matrix metalloproteinases, a large family of zinc-dependent proteases implicated in many...
9.
Gelain A, Mori M, Meneghetti F, Porta F, Basile L, Marverti G, et al.
Anticancer Res
. 2018 Dec;
39(1):135-144.
PMID: 30591450
Background/aim: The identification of a series of oxadiazole-based compounds, as promising antiproliferative agents, has been previously reported. The aim of this study was to explore the SAR of newly-synthesized oxadiazole...
10.
Ferla S, Netzler N, Ferla S, Veronese S, Enosi Tuipulotu D, Guccione S, et al.
Sci Rep
. 2018 Mar;
8(1):4129.
PMID: 29515206
Human norovirus causes approximately 219,000 deaths annually, yet there are currently no antivirals available. A virtual screening of commercially available drug-like compounds (~300,000) was performed on the suramin and PPNDS...